Clinical Trial Update: Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating gefitinib in combination with chemoradiation for resectable gastric cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC | Phase 1, Phase 2 | Status: TERMINATED